CR20220618A - Nuevas proteinas de unión a repeticiones de anquirina y sus usos - Google Patents

Nuevas proteinas de unión a repeticiones de anquirina y sus usos

Info

Publication number
CR20220618A
CR20220618A CR20220618A CR20220618A CR20220618A CR 20220618 A CR20220618 A CR 20220618A CR 20220618 A CR20220618 A CR 20220618A CR 20220618 A CR20220618 A CR 20220618A CR 20220618 A CR20220618 A CR 20220618A
Authority
CR
Costa Rica
Prior art keywords
proteins
ankyrin repeat
binding proteins
nucleic acids
repeat binding
Prior art date
Application number
CR20220618A
Other languages
English (en)
Inventor
Patrick Amstutz
Valerie Perrine Calabro
Marcel Walser
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of CR20220618A publication Critical patent/CR20220618A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a proteínas de unión recombinantes que comprenden uno o más dominios de repetición de anquirina diseñados con especificidad de unión para proteínas de espiga de coronavirus, ácidos nucleicos que codifican dichas proteínas, composiciones farmacéuticas que comprenden dichas proteínas o ácidos nucleicos, y el uso de dichas proteínas, ácidos nucleicos o composiciones farmacéuticas en el tratamiento de enfermedades por coronavirus, particularmente enfermedades causadas por el SARS–CoV–2.
CR20220618A 2020-05-06 2021-05-06 Nuevas proteinas de unión a repeticiones de anquirina y sus usos CR20220618A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063021024P 2020-05-06 2020-05-06
US202063020882P 2020-05-06 2020-05-06
US202063057477P 2020-07-28 2020-07-28
US202063069174P 2020-08-24 2020-08-24
US202163145192P 2021-02-03 2021-02-03
PCT/IB2021/000320 WO2021224686A1 (en) 2020-05-06 2021-05-06 Novel ankyrin repeat binding proteins and their uses

Publications (1)

Publication Number Publication Date
CR20220618A true CR20220618A (es) 2023-01-19

Family

ID=78412258

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220618A CR20220618A (es) 2020-05-06 2021-05-06 Nuevas proteinas de unión a repeticiones de anquirina y sus usos

Country Status (16)

Country Link
US (2) US11466062B2 (es)
EP (1) EP4146691A1 (es)
JP (1) JP2023525518A (es)
KR (1) KR20230006558A (es)
CN (1) CN115916815A (es)
AU (1) AU2021267411A1 (es)
BR (1) BR112022022456A2 (es)
CA (1) CA3176845A1 (es)
CL (1) CL2022003044A1 (es)
CO (1) CO2022016595A2 (es)
CR (1) CR20220618A (es)
IL (1) IL297940A (es)
MX (1) MX2022013945A (es)
PE (1) PE20231074A1 (es)
TW (1) TW202208404A (es)
WO (1) WO2021224686A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115003689A (zh) * 2019-12-11 2022-09-02 分子合作伙伴股份公司 具有改变的表面残基的经设计的锚蛋白重复结构域
CR20220618A (es) * 2020-05-06 2023-01-19 Molecular Partners Ag Nuevas proteinas de unión a repeticiones de anquirina y sus usos
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
TWI796597B (zh) * 2020-09-21 2023-03-21 長庚大學 使用紫蘇之經水萃取的產物來對抗冠狀病毒感染的方法
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
WO2023154841A2 (en) * 2022-02-11 2023-08-17 The Texas A&M University System Sars-cov-2 neutralizing synthetic proteins
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EA013615B1 (ru) 2004-11-12 2010-06-30 Байер Шеринг Фарма Акциенгезельшафт Рекомбинантный онколитический парамиксовирус и его применение
RU2412249C2 (ru) 2005-07-08 2011-02-20 Юниверсити Оф Цюрих Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов
WO2009040338A1 (en) 2007-09-24 2009-04-02 University Of Zürich Designed armadillo repeat proteins
KR101698362B1 (ko) 2008-11-03 2017-01-20 몰리큘라 파트너스 아게 Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN113278077A (zh) 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
JP2014519808A (ja) 2011-04-29 2014-08-21 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ４／ｉｌ１３に結合する反復タンパク質及び使用
SG11201408196RA (en) * 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
JP2015532306A (ja) 2012-10-15 2015-11-09 チューリッヒ大学 癌治療のための二重特異性ｈｅｒ２リガンド
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
JP6486908B2 (ja) 2013-05-31 2019-03-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
EP3277711B9 (en) 2015-04-02 2023-08-16 Molecular Partners AG Designed ankyrin repeat domains with binding specificity for serum albumin
NZ751689A (en) 2016-09-22 2021-07-30 Molecular Partners Ag Recombinant binding proteins and their use
JP2022535107A (ja) 2019-06-04 2022-08-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換え４－１ｂｂ結合タンパク質及びそれらの使用
US20220242973A1 (en) 2019-06-04 2022-08-04 Molecular Partners Ag Recombinant fap binding proteins and their use
CN114206908A (zh) 2019-06-04 2022-03-18 分子伴侣公司 具有改善的稳定性的经设计的锚蛋白重复结构域
AU2020289080A1 (en) 2019-06-04 2021-12-23 Molecular Partners Ag Multispecific proteins
JP2023506763A (ja) 2019-12-11 2023-02-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えペプチド－ｍｈｃ複合体結合タンパク質並びにそれらの生成及び使用
CN115003689A (zh) 2019-12-11 2022-09-02 分子合作伙伴股份公司 具有改变的表面残基的经设计的锚蛋白重复结构域
CR20220618A (es) * 2020-05-06 2023-01-19 Molecular Partners Ag Nuevas proteinas de unión a repeticiones de anquirina y sus usos

Also Published As

Publication number Publication date
US20210347835A1 (en) 2021-11-11
JP2023525518A (ja) 2023-06-16
CN115916815A (zh) 2023-04-04
US20220235103A1 (en) 2022-07-28
MX2022013945A (es) 2023-02-14
US11466062B2 (en) 2022-10-11
AU2021267411A1 (en) 2022-12-08
CL2022003044A1 (es) 2023-06-02
PE20231074A1 (es) 2023-07-17
TW202208404A (zh) 2022-03-01
IL297940A (en) 2023-01-01
BR112022022456A2 (pt) 2023-01-10
KR20230006558A (ko) 2023-01-10
CO2022016595A2 (es) 2022-12-09
CA3176845A1 (en) 2021-11-11
EP4146691A1 (en) 2023-03-15
WO2021224686A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
CR20220618A (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
SA517390092B1 (ar) مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل
PH12019500596A1 (en) Recombinant binding proteins and their use
MX2022007122A (es) Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
MX2017014082A (es) Nuevas proteinas especificas para cd137.
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
CY1117351T1 (el) Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
CR20220136A (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
BRPI1013877A2 (pt) Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
EA201270528A1 (ru) Композиции цитокинов семейства il-17 и их применение
IN2014CN00414A (es)
MX2022014326A (es) Proteinas multiespecificas.
BR112018014288A2 (pt) métodos e composições para o tratamento de doença neurológica
MX2022011394A (es) Composiciones y metodos para la induccion de una respuesta inmune.
MX2021014601A (es) Proteinas recombinantes de union a fap y su uso.
WO2022167816A3 (en) Antibodies
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
MX2023011978A (es) Captadores de cd70 novedosos basados en darpin.
MX2020009507A (es) Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
MX2021008126A (es) Vacuna de arnm.
AR122100A1 (es) Proteínas multiespecíficas